Cannabis and the Aging Brain: New Research Complicates the Picture in Productive Ways

Cannabis and the Aging Brain: New Research Complicates the Picture in Productive Ways

If you wanted to design a week's worth of research findings guaranteed to frustrate anyone seeking a simple answer about cannabis and brain health, this was it. Two significant studies landed within days of each other, each rigorous, each credible, each pointing in a subtly different direction — and together they illustrate exactly why the science of cannabis and cognition is so difficult to summarize in a headline.

The more alarming of the two arrived May 12 in Nature Mental Health, published by a research team led by Dr. Heather Ward at Vanderbilt University. The study drew on data from the North American Prodrome Longitudinal Study, which follows more than 1,000 individuals identified as being at "clinical high risk" for psychosis — meaning they have already shown early signs, such as brief or attenuated psychotic episodes, that place them in an elevated-risk population. The key finding: people who used both cannabis and tobacco heavily were nearly three times more likely to develop a full psychotic disorder, including schizophrenia, compared to those who used neither. Regular use of either substance alone was associated with elevated anxiety and depression, but the combined-use group showed the most alarming longitudinal outcomes.

The finding is significant precisely because it is specific. This is not a study claiming that cannabis causes psychosis in the general population — a much more contested claim that large epidemiological studies have struggled to support cleanly. Instead, it identifies a particular high-risk subgroup, a particular combination of behaviors, and a particular outcome. That specificity is what makes it clinically actionable. Dr. Ward noted that for clinicians working with patients showing early psychotic symptoms, the takeaway is clear: "stopping cannabis and tobacco co-use may improve mental health symptoms, and it is possible that stopping co-use could reduce risk of developing psychosis in the first place." For a patient population that already has one foot over a diagnostic threshold, that is meaningful information that can guide treatment conversations in the near term.

The second study, published simultaneously this week, involved Stanford University experts identifying five specific health risks for adults over 65 who use cannabis regularly: elevated cardiovascular risk, increased cancer risk, dependency potential, cognitive effects with heavy use, and dangerous interactions with commonly prescribed medications. This kind of practical risk taxonomy is exactly what the medical community has been asking for as older adult cannabis use rises sharply — driven by an aging population seeking alternatives to opioids and sleep medications. The researchers were careful to note that many older adults who use cannabis report genuine benefits for sleep, pain, and anxiety, but that the evidence base for those benefits remains soft, while the risks are becoming better characterized.

Taken together, these two studies don't cancel each other out. They occupy different parts of the risk landscape. The Vanderbilt study speaks to a narrow and identifiable high-risk population. The Stanford work speaks to a broad and growing population — older adults — where risk profiles are different from those of young people, who have historically been the default subject of cannabis research.

That distinction matters enormously because the cannabis conversation in clinical settings has almost always been conducted with young people as the implicit reference population. Yet data from the University of Utah Health and University of Colorado Boulder, published in JAMA Network Open, found that most older adults trying cannabis for the first time are motivated by sleep problems, chronic pain, or mental health concerns, and that the vast majority of those 169 first-time older adult users made their decision based on word of mouth rather than a conversation with a healthcare provider. That gap — between the self-medication happening at scale and the clinical guidance available to support it — is one of the most important unresolved problems in cannabis medicine right now.

Providing some positive counterpoint, earlier 2026 research from Yale and Oxford had found that lifetime cannabis use in older adults was not associated with accelerated cognitive decline or increased dementia risk, across data from hundreds of thousands of participants in the UK Biobank and US Million Veteran Program. The researchers were careful to note the limitations of observational data and the difficulty of characterizing dosage exposure, but the finding held up across Mendelian randomization analyses designed to test for causal relationships. It does not mean cannabis is safe for all older adults in all contexts, as this week's Stanford risk assessment makes clear, but it does challenge the assumption that any cannabis use in aging populations is necessarily an accelerant of cognitive deterioration.

For patients and clinicians navigating these findings, the honest takeaway is that cannabis science in 2026 is producing exactly what good science should: increasingly specific answers to increasingly specific questions. The era of "cannabis is dangerous" versus "cannabis is medicine" as competing monolithic claims is giving way to something more useful and more honest — an empirical map of who is at risk, under what conditions, and for what outcomes. That map is still being drawn, but this week added some important coordinates.